Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Recent research has focused on methods to mitigate scar tissue formation and arthrofibrosis
following surgery in hopes that patients may attain maximal range of motion goals, avoid
manipulation and secondary surgery (i.e. revision arthroplasty), and improve their function.
The synovial fluid milieu has also highlighted the role of local biochemical markers that may
be implicated in the development of arthrofibrosis. Losartan is an angiotensin receptor
blocker with inhibitory effects on transforming growth factor beta (TGF-b), largely
implicated in tissue repair and fibrosis by way of SMAD protein signaling suppression, and
has been used in orthopaedic sports medicine to prevent stiffness following hip arthroscopy.
To date, this has not commonly been used at NYU Langone in orthopedic surgery. The purpose of
this study is to evaluate the efficacy of losartan use pre- and post-operatively on range of
motion and the incidence of manipulation under anesthesia following total knee arthroplasty.